Type 2 Diabetes Patients Beware of Pioglitazone Treatments
The attorneys at Fears Nachawati are fighting for patients who have suffered from the side effects of pioglitazone treatments. Pioglitazone, marketed in the United States under the trade name Actos, has been popular since its release to the market and by 2008 had become the tenth best selling drug in the U.S., generating revenue of nearly $2.5 billion.
The popularity of Actos is easy to understand: pioglitazone has been shown to reduce the risk of conversion of prediabetes to Type 2 diabetes by more than 70 percent.
While the primary effects of Actos are positive, recent studies have revealed that for many patients the side effects of pioglitazone are simply unbearable. Several, independent investigations found that pioglitazone significantly increased the risk of bladder cancer in patients who took pioglitazone for more than two years.
You may have heard that the Food and Drug Administration (FDA) issued a drug safety advisory this summer. What you may not know is that France and Germany both adopted aggressive measures designed to curtail its prescription. France, in fact, suspended the use of pioglitazone altogether.
Tragically, these recent studies – and the suffering of numerous patients and their families – strongly suggest that Actos is a dangerous drug. Fortunately for victims, the attorneys at Fears Nachawati are using the judicial system to fight back. If you or one of your loved ones have been injured as a result of Actos, talk to our experts today. For your free consultation, call 1.866.545.8364 or email email@example.com.